[Form 4] BICYCLE THERAPEUTICS PLC Insider Trading Activity

Rhea-AI Filing Summary

Bicycle Therapeutics plc (BCYC) director Robert Charles Swanton reported a sale of 102 ordinary shares on 10/02/2025 at a price of $8.55 per share. The filing shows the sale was executed under a Rule 10b5-1 trading plan adopted on 10/14/2024, and the reporting person held 15,487 shares following the transaction. The form is a standard Section 16 filing reporting a non-derivative disposition by an insider; no options, grants, or other derivative transactions are reported.

Positive

• Sale executed under a Rule 10b5-1 plan, indicating pre-arranged trading instructions
• Director retains 15,487 shares after the sale, showing continued ownership

Negative

• None.

Insights

Insider Transactions Analyst

Director sold a small block under a pre-set 10b5-1 plan.

The director reported a disposition of 102 ordinary shares at $8.55 on 10/02/2025, reducing direct holdings to 15,487 shares. The filing explicitly states the sale was made pursuant to a Rule 10b5-1 trading plan adopted on 10/14/2024, which provides an affirmative defense for trades made under pre-established instructions.

The transaction size is modest relative to typical director holdings, and no derivative activity or new grants are disclosed. Investors may note the plan origin date and the remaining share count as near-term, monitorable items for future Form 4 activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Swanton Robert Charles

(Last) (First) (Middle)

C/O BICYCLE THERAPEUTICS PLC

BLOCKS A & B, PORTWAY BUILDING

(Street)

CAMBRIDGE X0 CB21 6GS

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BICYCLE THERAPEUTICS PLC [ BCYC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	10/02/2025		S(1)		102	D	$8.55	15,487	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on October 14, 2024.

	/s/ Travis Thompson, Attorney-in-Fact	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BCYC insider Robert Charles Swanton report on Form 4?

He reported a sale of 102 ordinary shares at $8.55 per share on 10/02/2025 and held 15,487 shares after the transaction.

Was the BCYC sale part of a 10b5-1 plan?

Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on 10/14/2024.

Did the Form 4 report any option exercises or derivative transactions for BCYC?

No. Table II for derivative securities shows no derivative activity; only a non-derivative sale is reported.

How much did the director receive per share in the reported BCYC sale?

The reported price was $8.55 per share.

When was the Form 4 signed and filed for the BCYC transaction?

The signature block shows the form was signed by an attorney-in-fact on 10/06/2025.